Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Santhera Plans to Announce Regulatory Feedback for Raxone® in DMD and 2017 Preliminary Key Financial Figures

Santhera Pharmaceuticals Holding AG
Posted on: 19 Jan 18

Liestal, Switzerland, January 19, 2018 - Santhera Pharmaceuticals (SIX: SANN) expects to announce feedback from the CHMP on its Marketing Authorization Application (MAA) for Raxone® in Duchenne muscular dystrophy (DMD) on January 26, 2018, and will publish the Company's preliminary key financial figures for 2017 on January 29, 2018.

Announcement of CHMP opinion on MAA for Raxone® in DMD expected for January 26, 2018
Santhera expects to receive an opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its MAA filed as Type II extension application for Raxone® (idebenone) in DMD by January 26, following a re-examination procedure. Santhera expects to announce the CHMP opinion on January 26, 2018, at 07:00 hrs CET. On the same day, at 14:00 hrs CET, Thomas Meier, PhD, CEO of Santhera, will hold an investor conference call to discuss the outcome.

Announcement of 2017 Key Financials on January 29, 2018
Santhera will release its preliminary key financial figures for 2017 and provide a corporate update on January 29, 2018, at 07:00 hrs CET. In an investor conference call scheduled the same day at 14:00 hrs CET, Thomas Meier, PhD, CEO of Santhera, will discuss the key financials and the development of the business.

The 2017 Annual Report with full financial results will be published on March 20, 2018, at 07:00 hrs CET.

Access to conference calls
Participants can access either conference call by dialing one of the following numbers about 10 minutes before the call is due to start:
+41 (0)58 310 50 00 (Europe)
+44 (0)207 107 0613 (UK)
+1 (1)631 570 5613 (USA)

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), Santhera has filed a Marketing Authorization Application in the European Union and Switzerland for DMD patients with respiratory function decline who are not taking glucocorticoids. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and another product - omigapil - for congenital muscular dystrophy (CMD), both also areas of high unmet medical need. For further information, please visit the Company's website .
Raxone ® is a trademark of Santhera Pharmaceuticals.       

For further information please contact: or

Eva Kalias, Vio Consult
Phone: +41 78 671 98 86

For Investors: or

Christoph Rentsch, Chief Financial Officer                                      Hans Vitzthum, LifeSci Advisors
Europe: +41 61 906 89 65                                                                 US: +1 212 915 2568                                          

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

News release Corporate Calendar

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire

Last updated on: 22/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.